Andy Cohen TRT: A Clinical Interpretation of His Testosterone Therapy

What Andy Cohen Has Said About TRT

Andy Cohen has been more transparent about hormone therapy than nearly any other public figure in mainstream American entertainment. In multiple interviews and on his SiriusXM radio program "Radio Andy," Cohen described starting testosterone replacement therapy and noted changes in energy, mood, and physical performance. He framed the decision as a response to symptoms he experienced in his late 40s and early 50s, a period that aligns clinically with the age at which late-onset hypogonadism is most commonly diagnosed.

His Public Statements

Cohen did not describe his regimen in precise pharmacological terms, which is common when non-clinicians discuss their care. He referenced feeling fatigued and experiencing reduced vitality before beginning TRT, and he credited the therapy with meaningful improvements. Those reported symptoms map directly onto the clinical criteria that endocrinologists use to evaluate hypogonadism. The Endocrine Society's 2018 clinical practice guideline states: "We recommend making a diagnosis of androgen deficiency only in men with consistent symptoms and signs and unequivocally low serum testosterone concentrations." [1]

Why His Openness Matters Clinically

Public figures discussing TRT reduce the stigma that prevents symptomatic men from seeking evaluation. The American Urological Association estimates that approximately 2.4 million American men between 40 and 69 are hypogonadal, yet many go undiagnosed. [2] Cohen's willingness to name his therapy by name gives clinicians an opening to have similar conversations with hesitant patients.

What Is TRT and Who Qualifies?

Testosterone replacement therapy restores circulating testosterone to physiologic levels in men whose testes produce insufficient amounts. The therapy does not build supraphysiologic levels in a compliant clinical regimen. It targets the normal adult male range.

Diagnostic Criteria

Diagnosis requires two things: symptoms consistent with hypogonadism and biochemical confirmation. Biochemical confirmation means two separate morning serum total testosterone measurements below 300 ng/dL, measured by a reliable assay. [1] Symptoms that drive evaluation include reduced libido, fatigue, depressed mood, decreased muscle mass, increased visceral fat, and poor concentration.

Free testosterone measurement adds diagnostic precision when sex hormone-binding globulin (SHBG) levels are elevated, as SHBG rises with age and obesity and may make total testosterone appear normal when bioavailable testosterone is actually low. [3]

Age and Prevalence

Testosterone declines at roughly 1 to 2% per year after age 30. [4] By age 70, approximately 20% of men meet biochemical criteria for hypogonadism. In men Cohen's age (mid-50s), prevalence is estimated at 12 to 15% depending on the diagnostic threshold used. [4] His reported symptom timeline is entirely consistent with late-onset hypogonadism appearing in the early fifth decade.

Available TRT Formulations and How They Differ

Several approved formulations exist. Each has distinct pharmacokinetics, adherence profiles, and risk considerations.

Intramuscular Testosterone Cypionate

Testosterone cypionate (Depo-Testosterone) given intramuscularly every 1 to 2 weeks remains the most widely prescribed formulation in the United States, partly because of cost. A standard starting dose is 100 to 200 mg every two weeks, though weekly injections of 50 to 100 mg produce more stable serum levels and fewer trough symptoms. [1] Peak levels occur 24 to 72 hours post-injection; trough levels appear just before the next dose. This peak-trough variability is the main clinical drawback.

Transdermal Gels and Patches

Testosterone gels (AndroGel 1%, AndroGel 1.62%, Testim, Vogelxo) provide daily dosing and stable serum levels without injection-associated peaks. The FDA-approved starting dose for AndroGel 1.62% is 40.5 mg daily, titrated based on morning testosterone levels measured 14 days after initiation or dose change. [5] Transfer to female partners or children is a documented risk requiring counseling on application site covering.

Subcutaneous Pellets

Testosterone pellets (Testopel) are implanted subcutaneously every 3 to 6 months. Each pellet delivers approximately 75 mg of testosterone. Typical implants use 6 to 12 pellets. Serum levels peak at 1 month and decline gradually. [6] The insertion procedure carries a small risk of pellet extrusion (reported at roughly 2 to 3% per implant cycle). Pellets suit patients who prefer infrequent intervention and can maintain consistent monitoring.

Subcutaneous Injections

Self-administered subcutaneous testosterone cypionate at 50 to 100 mg weekly is increasingly common in direct-to-patient telehealth models. Subcutaneous delivery produces more stable peak-to-trough ratios than intramuscular injection at equivalent doses. [7] This formulation is not separately FDA-approved but uses the same testosterone cypionate injectable solution as the intramuscular route.

What Clinical Monitoring Looks Like

TRT without monitoring is poor medicine. Cohen has not detailed his monitoring protocol publicly, but any responsibly managed TRT regimen follows a structured schedule.

Baseline Labs

Before initiating TRT, clinicians obtain: two morning total testosterone measurements, LH and FSH (to distinguish primary from secondary hypogonadism), complete blood count (CBC), comprehensive metabolic panel, fasting lipid panel, PSA, and hematocrit. [1] Men over 40 with elevated PSA or abnormal digital rectal exam require urology clearance before starting.

Ongoing Monitoring

At 3 and 6 months after initiation, and annually thereafter, monitoring includes serum testosterone (drawn at the appropriate time relative to dose), hematocrit, PSA, and symptom assessment. [1] Hematocrit above 54% requires dose reduction or temporary discontinuation to reduce thrombotic risk. The Endocrine Society guideline notes that erythrocytosis is the most common adverse effect of TRT, occurring in approximately 5.7% of treated men in observational data. [1]

PSA and Prostate Considerations

TRT is contraindicated in men with known or suspected prostate cancer. For men with no diagnosis, TRT does not appear to cause prostate cancer, but it may accelerate growth of subclinical disease. PSA should remain stable on therapy. A rise of more than 1.4 ng/mL above baseline in any 12-month period during the first two years warrants urology referral. [1]

Cardiovascular Safety: What the Evidence Shows

The cardiovascular safety of TRT has been debated for over a decade. Two early observational studies raised concerns about increased myocardial infarction risk, prompting an FDA safety review in 2014. [5] That review led to updated labeling requiring disclosure of cardiovascular risk. The evidence picture has since become substantially clearer.

The TRAVERSE Trial

The TRAVERSE trial (Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men, N=5,246) was a randomized, placebo-controlled, double-blind trial designed specifically to answer the cardiovascular safety question. [8] Published in the New England Journal of Medicine in 2023, TRAVERSE found that testosterone replacement with daily transdermal testosterone 1.62% gel did not increase major adverse cardiovascular events (MACE) compared to placebo over a median 33-month follow-up in hypogonadal men aged 45 to 80 with cardiovascular risk factors or disease. [8]

The TRAVERSE authors wrote: "Testosterone replacement was noninferior to placebo with respect to the incidence of major adverse cardiovascular events." [8] That finding applies to men using TRT at therapeutic doses under medical supervision. It does not extend to supraphysiologic dosing seen in anabolic steroid misuse.

TRAVERSE did find higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone arm, each reaching statistical significance. [8] Those findings inform current counseling, especially for men with pre-existing atrial fibrillation or thromboembolic history.

Prior Randomized Evidence

The Testosterone Trials (TTrials), a coordinated group of seven randomized placebo-controlled trials in 788 men aged 65 and older with low testosterone, found that TRT improved sexual function, physical performance, bone mineral density, and anemia compared to placebo. [9] No significant increase in cardiovascular events was observed in TTrials, though the study was not powered for cardiovascular endpoints.

Testosterone and Body Composition: What TRT Actually Does

Cohen cited energy and physical performance as motivators, which aligns with the documented physiologic effects of testosterone repletion.

Lean Mass and Fat Mass

A meta-analysis of 58 randomized controlled trials published in the Journal of Clinical Endocrinology and Metabolism found that TRT increased lean body mass by a mean of 1.6 kg and decreased fat mass by a mean of 1.6 kg compared to placebo, with the effect size varying by baseline testosterone and formulation. [10] These are modest changes. TRT is not a body-recomposition drug in the way anabolic steroids are used illicitly. The changes reflect restoration of physiologic hormone levels, not pharmacologic enhancement.

Mood, Energy, and Quality of Life

Men with symptomatic hypogonadism report depressive symptoms at higher rates than eugonadal men. A 2019 meta-analysis in JAMA Psychiatry found that TRT significantly reduced depressive symptoms in hypogonadal men compared to placebo, with a standardized mean difference of 0.21 (P<0.001). [11] The effect was most pronounced in men with confirmed biochemical hypogonadism rather than normal testosterone with depressive symptoms.

Fatigue and reduced vitality improve in a meaningful proportion of men on TRT. The TTrials showed statistically significant improvements in sexual desire and activity at 12 months, with moderate improvements in walking distance and mood. [9]

Clinical Interpretation: How Cohen's Reported Experience Fits the Evidence

Based on Cohen's public statements, his clinical picture is consistent with late-onset hypogonadism presenting in the late fourth to early fifth decade. He reported fatigue, reduced vitality, and changes in physical performance before starting therapy, and he has described meaningful improvements since. Those reported outcomes map to the endpoints showing statistical benefit in controlled trials.

What We Can Infer (Labeled as Inference)

Cohen has not published lab values or disclosed the specific formulation, dose, or prescriber. The following is clinical inference based on his described symptom pattern and response, not confirmed fact.

His symptom onset in his late 40s is consistent with late-onset hypogonadism. His reported improvements in energy and vitality are consistent with testosterone repletion effects documented in the TTrials and TRAVERSE populations. The formulation is unknown. Given the growing prevalence of telehealth TRT, subcutaneous testosterone cypionate or a transdermal gel are plausible options, but this is inference only.

What the Guidelines Say About Men in His Demographic

The Endocrine Society guideline recommends TRT for men with symptomatic hypogonadism who have no contraindications, stating: "We suggest that clinicians measure testosterone concentration before starting testosterone therapy and repeat the measurement to confirm the diagnosis." [1] For a 56-year-old man with consistent symptoms and confirmed low testosterone, TRT is a guideline-supported intervention.

Men in this age group benefit from prostate surveillance, hematocrit monitoring, and lipid reassessment. None of this monitoring data is publicly available for Cohen, so no clinical judgment about his individual management is made here.

Contraindications and Who Should Not Use TRT

Not every symptomatic man is a candidate. Absolute contraindications include prostate cancer, breast cancer, hematocrit above 54%, severe untreated obstructive sleep apnea, uncontrolled heart failure, and desire for fertility preservation. [1]

Fertility Consideration

TRT suppresses the hypothalamic-pituitary-gonadal axis, reducing LH and FSH and thereby suppressing intratesticular testosterone and spermatogenesis. Men who wish to preserve fertility should not use TRT without concurrent HCG (human chorionic gonadotropin) to maintain intratesticular testosterone. Cohen, who has two children via surrogacy, is not on record as having fertility concerns at this stage.

Sleep Apnea

Testosterone therapy may worsen obstructive sleep apnea by altering upper airway tone and chemoreceptor sensitivity. [1] Men starting TRT should be screened for sleep apnea symptoms, and those with untreated moderate-to-severe OSA should address it before or concurrently with testosterone initiation.

TRT in Telehealth: The Model Cohen May Be Using

Direct-to-patient TRT telehealth platforms have expanded access substantially since 2019. These models typically involve asynchronous or synchronous physician consultation, home phlebotomy for baseline and monitoring labs, and mail-order dispensing of injectables or gels. FDA-approved testosterone products are used. The clinical protocols in legitimate telehealth TRT platforms follow the same Endocrine Society monitoring standards as brick-and-mortar endocrinology offices.

Cohen has not specified whether his prescriber is a traditional endocrinologist, a men's health specialist, or a telehealth platform. All three models can deliver appropriate care when monitoring protocols are followed.